Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.51 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.51 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.51 |
| ▸ | TGFBR1 | P36897 | 14/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.47 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.47 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.47 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.47 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5162700 | 0.93 | MAPK14 (0.51) | MAPK14CSNK1DCSNK1ETGFBR1CSNK1A1 | |
| SCHEMBL27686266 | 0.86 | MAPK14 (0.40) | MAPK14CSNK1DCSNK1ETGFBR1RIPK2 | |
| SCHEMBL5138613 | 0.85 | MAPK14 (0.52) | MAPK14CSNK1DCSNK1ETGFBR1CSNK1A1 | |
| SCHEMBL5497054 | 0.83 | MAPK14 (0.49) | MAPK14TGFBR1PRKD1CYP1A2CYP2D6 | |
| SCHEMBL5113786 | 0.80 | TGFBR1 (0.58) | MAPK14TGFBR1RIPK2ACVR1BPRKD1 | |
| SCHEMBL5137971 | 0.79 | TGFBR1 (0.56) | MAPK14CSNK1DCSNK1ETGFBR1CSNK1A1 | |
| SCHEMBL5138427 | 0.79 | TGFBR1 (0.56) | MAPK14CSNK1DCSNK1ETGFBR1CSNK1A1 | |
| SCHEMBL27705251 | 0.79 | MAPK14 (0.40) | MAPK14CSNK1DCSNK1ETGFBR1RIPK2 | |
| SCHEMBL5497694 | 0.78 | TGFBR1 (0.75) | MAPK14CSNK1DCSNK1ETGFBR1CSNK1A1 | |
| SCHEMBL5500967 | 0.75 | MAPK14 (0.49) | MAPK14TGFBR1PRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771171-A1 | USE OF ALK 5 INHIBITORS TO MODULATE OR INHIBIT MYOSTATIN ACTIVITY LEADING TO INCREASED LEAN TISSUE ACCRETION IN ANIMALS | Schering-Plough Ltd. (CH) | 2007-04-11 | — | — | EP | claimed |
| US-20060194845-A1 | Use of ALK 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals | SCHERING CORPORATION | 2006-08-31 | — | — | US | claimed |
| WO-2006025988-A1 | USE OF ALK 5 INHIBITORS TO MODULATE OR INHIBIT MYOSTATIN ACTIVITY LEADING TO INCREASED LEAN TISSUE ACCRETION IN ANIMALS | SCHERING-PLOUGH LTD. (CH) | 2006-03-09 | — | — | WO | claimed |
| US-6906089-B2 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-14 | — | — | US | claimed |
| EP-1268465-B1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-06-01 | — | — | EP | claimed |
| US-20030149277-A1 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | claimed |
| EP-1268465-A1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-02 | — | — | EP | claimed |
| WO-2001072737-A1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-04 | — | — | WO | claimed |
| EP-1771171-A1 | USE OF ALK 5 INHIBITORS TO MODULATE OR INHIBIT MYOSTATIN ACTIVITY LEADING TO INCREASED LEAN TISSUE ACCRETION IN ANIMALS | Schering-Plough Ltd. (CH) | 2007-04-11 | — | — | EP | disclosed |
| US-20060194845-A1 | Use of ALK 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals | SCHERING CORPORATION | 2006-08-31 | — | — | US | disclosed |
| WO-2006025988-A1 | USE OF ALK 5 INHIBITORS TO MODULATE OR INHIBIT MYOSTATIN ACTIVITY LEADING TO INCREASED LEAN TISSUE ACCRETION IN ANIMALS | SCHERING-PLOUGH LTD. (CH) | 2006-03-09 | — | — | WO | disclosed |
| US-6906089-B2 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1268465-B1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20030149277-A1 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | disclosed |
| EP-1268465-A1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001072737-A1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194845-A1 | Use of ALK 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals | ALK, ACVR1, MSTN | MAPK14 1382/4885CSNK1D 4113/4885CSNK1E 3349/4885 |
| US-20030149277-A1 | Triarylimidazole derivatives as cytokine inhibitors | IL2, IL2RA, IL6ST | MAPK14 306/4885CSNK1D 79/4885CSNK1E 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.